AstraZeneca (AZN) Expected to Announce Earnings on Tuesday

AstraZeneca (NASDAQ:AZN) is expected to release its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect AstraZeneca to post earnings of $1.09 per share and revenue of $15.4052 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 6:45 AM ET.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 EPS. On average, analysts expect AstraZeneca to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Trading Up 102.6%

Shares of NASDAQ:AZN opened at $187.98 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $583.07 billion, a PE ratio of 62.45, a P/E/G ratio of 1.59 and a beta of 0.34. AstraZeneca has a 1 year low of $61.24 and a 1 year high of $192.79. The firm has a fifty day moving average price of $94.22 and a 200 day moving average price of $85.32.

Institutional Trading of AstraZeneca

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of AstraZeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after buying an additional 11,690 shares in the last quarter. Amundi raised its stake in shares of AstraZeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after acquiring an additional 3,618 shares during the last quarter. Jump Financial LLC boosted its holdings in shares of AstraZeneca by 898.4% in the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in AstraZeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AZN. Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating for the company. HSBC reaffirmed a “buy” rating and set a $108.00 target price on shares of AstraZeneca in a research report on Wednesday, December 10th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 price objective on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.